MedTrace Logo

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

NCT04627831 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-04-11

No results posted yet for this study

Summary

Randomized parallel group study comparing the renal safety of Captisol-Enabled™ Iohexol (CE-Iohexol) Injection and Omnipaque™ (Iohexol) Injection in patients with impaired renal function undergoing coronary angiography.

Conditions

  • Contrast-induced Nephropathy

Interventions

DRUG

CE-Iohexol

Captisol-Enabled™ Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.

DRUG

Iohexol

Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.

Sponsors & Collaborators

  • CyDex Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Ligand Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Keith Marschke, PhD · Ligand Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2023-03-31
Completion
2023-04-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04627831 on ClinicalTrials.gov